var data={"title":"Theophylline: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Theophylline: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7037?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=theophylline-drug-information\" class=\"drug drug_general\">see &quot;Theophylline: Drug information&quot;</a> and <a href=\"topic.htm?path=theophylline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Theophylline: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226552\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Elixophyllin;</li>\n      <li>Theo-24;</li>\n      <li>Theochron</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226553\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pulmophylline;</li>\n      <li>Theo ER;</li>\n      <li>Theolair;</li>\n      <li>Uniphyl</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062538\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Bronchodilator</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Respiratory Stimulant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Theophylline Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445184\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Dose should be calculated using ideal body weight and individualized by serum concentrations. Due to the longer half-life compared to older patients, the time to achieve steady-state serum concentrations is prolonged in neonates (see theophylline half-life); serum theophylline concentrations should be drawn after 48-72 hours of therapy (usually 72 hours in neonates); repeat values should be obtained 3 days after each change in dosage or weekly if on a stabilized dosage. If renal function decreased, consider dose reduction and additional monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Apnea of prematurity:</b> Oral: Immediate release oral solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: 5-6 mg/kg/dose (Bhatta-Metta, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: 2-6 mg/kg/<b>day</b> divided every 8-12 hours (Bhatta-Mehta, 2003; Henderson-Smart, 2011; Skouroliakou, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bronchospasm, neonatal lung disease:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: 4.6 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Premature neonates PNA &lt;24 days: 1 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Premature neonates PNA &ge;24 days: 1.5 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Full-term neonates: Total daily dose may be calculated using equation below; divide into 3 equal doses and administer at 8-hour intervals</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">Total daily dose (mg/<b>day</b>) = [(0.2 x age in weeks) +5] x (weight in kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from aminophylline (IV) to theophylline therapy: In premature neonates, the same dose may be used; evaluate serum concentrations at 48 hours or sooner if symptoms indicate.</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <b>Dosing adjustment in renal impairment:</b> Dose reduction and frequent monitoring of serum theophylline concentrations are required in neonates with decreased renal function; 50% of dose is excreted unchanged in the urine of neonates.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062531\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=theophylline-drug-information\" class=\"drug drug_general\">see &quot;Theophylline: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Doses should be individualized based on steady-state serum concentrations; theophylline pharmacokinetics have age-dependent factors which may alter required doses particularly in pediatric patients. For obese patients, ideal body weight should be used for dosage calculation.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Acute symptoms; asthma or other chronic lung conditions:</b> <b>Note:</b> Not recommended for the treatment of asthma exacerbations (NAEPP 2007). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Loading dose:</span> <b>Note:</b> Doses presented intended to achieve a serum level of approximately 10 mcg/mL; loading doses should be given intravenously (preferred) or with a rapidly absorbed oral product (not an extended release product). On the average, for every 1 mg/kg theophylline given, blood concentrations will rise 2 mcg/mL. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Patients <b>not</b> currently receiving methylxanthines:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 4.6 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: Immediate release product: 5 mg/kg  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Patients currently receiving methylxanthines:</i> A loading dose is not recommended without first obtaining a serum theophylline concentration in patients who have received aminophylline or theophylline within the past 24 hours. The loading dose should be calculated as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Dose = (C desired &ndash; C measured) (V<sub>d</sub>) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">C desired = desired serum theophylline concentration </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">C measured = measured serum theophylline concentration </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Maintenance dose:</span> Continuous IV infusion: <b>Note:</b> Dosing presented is to achieve a target concentration of 10 mcg/mL. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum concentration measurements during the first 12- to 24-hour period.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 4 to 6 weeks: 1.5 mg/kg/dose every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 6 to 52 weeks: Dose (mg/kg/<b>hour</b>) = (0.008 X age in weeks) + 0.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 1 to &lt;9 years: 0.8 mg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 9 to &lt;12 years: 0.7 mg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents 12 to &lt;16 years (otherwise healthy, nonsmokers): 0.5 mg/kg/<b>hour</b>; maximum daily dose: 900 mg/<b>day</b> unless serum concentrations indicate need for larger dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents 12 to &lt;16 years (cigarette or marijuana smokers): 0.7 mg/kg/<b>hour</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents 16 to 18 years (otherwise healthy, nonsmokers): 0.4 mg/kg/<b>hour</b>; maximum dose: 900 mg/<b>day</b> unless serum concentrations indicate need for larger dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiac decompensation, cor pulmonale, hepatic dysfunction, sepsis with multiorgan failure, shock: Initial: 0.2 mg/kg/<b>hour</b>; maximum dose: 400 mg/<b>day</b> unless serum concentrations indicate need for larger dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chronic conditions, asthma or other chronic lung conditions:</b> <b>Note:</b> Increase dose only if tolerated. Consider lowering dose or using a slower titration if caffeine-like adverse events occur. Smaller doses given more frequently may be used in patients with a more rapid metabolism to prevent breakthrough symptoms which could occur due to low trough concentration prior to the next dose. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Immediate release formulation:</i> Oral: <b>Note:</b> If at risk for impaired clearance or not feasible to monitor serum theophylline concentrations then do not exceed 16 mg/kg/<b>day</b>; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Manufacturer's labeling:</span> Frequency based upon age.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants: Total daily dose (mg/day) = [(0.2 x age in weeks) + 5] x (weight in kg); frequency is based on age </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dosing interval:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&le;26 weeks: Divide in 3 equal doses and administer every 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&gt;26 weeks: Divide in 4 equal doses and administer every 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents 1 to 15 years and &le;45 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Days 1 to 3: 12 to 14 mg/kg/<b>day</b> in divided doses every 4 to 6 hours; maximum daily dose: 300 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Days 4 to 6: 16 mg/kg/<b>day</b> in divided doses every 4 to 6 hours; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Maintenance: 20 mg/kg/<b>day</b> in divided doses every 4 to 6 hours; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents &gt;45 kg or Adolescents &ge;16 years: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Days 1 to 3: 300 mg/<b>day</b> in divided doses every 6 to 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Days 4 to 6: 400 mg/<b>day</b> in divided doses every 6 to 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Maintenance: 600 mg/<b>day</b> in divided doses every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Alternate dosing; age-directed</span> (Kliegman 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 1 to &lt;9 years: 20 to 24 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children 9 to 12 years: 16 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents &gt;12 to 16 years (nonsmokers): 13 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &gt;12 years and Adolescents (smokers): 16 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adolescents &gt;16 years (nonsmokers): 10 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Extended release formulations:</i> Oral: <b>Note:</b> If at risk for impaired clearance or not feasible to monitor serum theophylline concentrations then do not exceed 16 mg/kg/<b>day</b>; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Manufacturer's labeling:</span></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;6 years and Adolescents &lt;16 years, weighing &le;45 kg:  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Initial: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Days 1 to 3: 12 to 14 mg/kg/<b>day</b>; maximum daily dose: 300 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Days 4 to 6: 16 mg/kg/<b>day</b>; maximum daily dose: 400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Maintenance: 20 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dosing interval (product specific): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">12-hour extended release tablets: Children &ge;6 years and Adolescents: Divide in 2 equal doses and administer every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">24-hour extended release tablets: Children &ge;12 years and Adolescents: Administer every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children &ge;6 years and Adolescents, weighing &gt;45 kg or Adolescents &ge;16 years: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">12-hour extended release tablets: Children &ge;6 years and Adolescents, weighing &gt;45 kg or Adolescents &ge;16 years: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Initial: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Days 1 to 3: 300 mg/<b>day</b> in divided doses every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Days 4 to 6: 400 mg/<b>day</b> in divided doses every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Maintenance: 600 mg/<b>day</b> in divided doses every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">24-hour extended release tablets: Children &ge;12 years and Adolescents, weighing  &gt;45 kg or Adolescents &ge;16 years:  </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Initial: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Days 1 to 3: 300 to 400 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">Days 4 to 6: 400 to 600 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">Maintenance: Titrate according to serum concentrations </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <span style=\"text-decoration: underline\">Alternate dosing; age-directed</span> (Kliegman 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 6 to &lt;9 years: 20 to 24 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children 9 to 12 years: 16 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children and Adolescents &gt;12 to 16 years (nonsmokers): 13 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children &gt;12 years and Adolescents (smokers): 16 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Adolescents &gt;16 years (nonsmokers): 10 mg/kg/<b>day</b>; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Acute symptoms:</b> Manufacturer's labeling: <b>Note:</b> Not recommended for the treatment of asthma exacerbations (NAEPP 2007). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Loading dose: <b>Note:</b> Doses presented intended to achieve a serum concentration of approximately 10 mcg/mL; loading doses should be given intravenously (preferred) or with a rapidly absorbed oral product (not an extended release product). On the average, for every 1 mg/kg theophylline given, blood concentrations will rise 2 mcg/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Patients <b>not</b> currently receiving aminophylline or theophylline: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 4.6 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: Immediate release product: 5 mg/kg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Patients currently receiving aminophylline or theophylline: A loading dose is not recommended without first obtaining a serum theophylline concentration in patients who have received aminophylline or theophylline within the past 24 hours. The loading dose should be calculated as follows: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Dose = (C desired &ndash; C measured) (V<sub>d</sub>) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">C desired = desired serum theophylline concentration </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">C measured = measured serum theophylline concentration </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Maintenance dose: Continuous IV infusion: <b>Note:</b> Dosing presented is to achieve a target concentration of 10 mcg/mL. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum concentration measurements during the first 12- to 24-hour period. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults &le;60 years (otherwise healthy, nonsmokers): 0.4 mg/kg/<b>hour</b>; maximum daily dose: 900 mg/<b>day</b> unless serum concentrations indicate need for larger dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults &gt;60 years: 0.3 mg/kg/<b>hour</b>; maximum daily dose: 400 mg/<b>day</b> unless serum levels indicate need for larger dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chronic conditions:</b> Oral: <b>Note:</b> Increase dose only if tolerated. Consider lowering dose or using a slower titration if caffeine-like adverse events occur. Smaller doses given more frequently may be used in patients with a more rapid metabolism to prevent breakthrough symptoms which could occur due to low trough concentration prior to the next dose.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release oral solution: Initial dose: 300 mg/<b>day</b> administered in divided doses every 6 to 8 hours; maintenance: 400 to 600 mg/day (maximum daily dose: 600 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended release formulations: Initial dose: 300 to 400 mg once daily; maintenance: 400 to 600 mg once daily (maximum daily dose: 600 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosage adjustment based on serum theophylline concentrations:</b> Infants, Children, Adolescents, and Adults: <b>Note:</b> Recheck serum theophylline concentrations after 3 days when using oral dosing, or after 12 hours (children) or 24 hours (adults) when dosing intravenously. Patients maintained with oral therapy should be reassessed at 6- to 12-month intervals, when clinically indicated or if concomitant medication is added which may affect theophylline serum concentration. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&lt;9.9 mcg/mL: If tolerated, but symptoms remain, increase dose by ~25%. Recheck serum theophylline concentrations. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 to 14.9 mcg/mL: Maintain dosage if tolerated. Recheck serum concentrations at 24-hour intervals (for acute IV dosing) or at 6- to 12-month intervals (for oral dosing). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 to 19.9 mcg/mL: Consider 10% dose reduction to improve safety margin even if dose is tolerated. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 to 24.9 mcg/mL: Decrease dose by ~25%. Recheck serum concentrations. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 to 30 mcg/mL: Skip next dose (oral) or stop infusion for 12 hours (children) or 24 hours (adults) and decrease subsequent doses by at least 25%. Recheck serum concentrations. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&gt;30 mcg/mL: Stop dosing and treat overdose; if resumed, decrease subsequent doses by at least 50%. Recheck serum concentrations. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 1 to 3 months: Consider dose reduction and frequent monitoring of serum theophylline concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants &gt;3 months, Children, Adolescents, and Adults: No adjustment necessary </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: Infants, Children, Adolescents, and Adults: Dose reduction and frequent monitoring of serum theophylline concentration are required in patients with decreased hepatic function (eg, cirrhosis, acute hepatitis, cholestasis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Manufacturer's labeling: Infants, Children, Adolescents, and Adults: Initial: 0.2 mg/kg/<b>hour</b>; maximum daily dose: 400 mg/<b>day</b> unless serum concentrations indicate need for larger dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226525\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Theo-24: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Theo-24: 200 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Theo-24: 300 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Theo-24: 400 mg [contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Elixir, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elixophyllin: 80 mg/15 mL (473 mL) [contains alcohol, usp, fd&amp;c red #40, saccharin sodium; mixed fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mg (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 80 mg/15 mL (15 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 12 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Theochron: 100 mg, 200 mg, 300 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg, 200 mg, 300 mg, 450 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mg, 600 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226511\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062543\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer on an empty stomach, 1 hour before or 2 hours after a meal. Sustained release preparations should be administered with a full glass of water, whole or cut by half only; do not crush; sustained release capsule forms may be opened and sprinkled on soft foods; do not chew or crush beads </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: Premix IV infusion bags available, administer loading dose over 30 minutes; rate for continuous IV infusion dependent upon dosage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6871827\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule: Store below 25&deg;C (77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elixir, oral solution Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); avoid exposure to excessive heat.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store at 25&deg;C (77&deg;F). Avoid excessive heat. Brief exposure up to 40&deg;C (104&deg;F) or up to 2 weeks to ultraviolet or fluorescent light does not adversely affect the product. Protect from freezing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062542\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of symptoms and reversible airway obstruction due to chronic asthma, chronic bronchitis, COPD, or other chronic lung diseases [Immediate release oral solution: FDA approved in all ages; Extended release 12 hour tablets: FDA approved in ages &ge; 6 years and adults; Extended release 24 hour capsules (Theo-24&reg;) and tablets: FDA approved in ages &ge;12 years and adults); has also been used for treatment of idiopathic apnea of prematurity  and to increase diaphragmatic contractility </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The Global Initiative for Asthma Guidelines (2009) and the National Asthma Education and Prevention Program Guidelines (2007) do not recommend oral theophylline as a long-term control medication for asthma in children &le;5 years of age; use has been shown to be effective as an add-on (but not preferred) agent in older children, adolescents, and adults with severe asthma treated with inhaled or oral glucocorticoids. The guidelines do not recommend theophylline for the treatment of exacerbations of asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Adjunctive treatment of acute exacerbations of asthma and other chronic lung diseases (eg, chronic bronchitis, emphysema) (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226604\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events observed at therapeutic serum levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac flutter, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, hyperactivity (children), insomnia, restlessness, seizure, status epilepticus (nonconvulsive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypercalcemia (with concomitant hyperthyroid disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Gastroesophageal reflux (aggravation), gastrointestinal ulcer (aggravation), nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Difficulty in micturition (elderly males with prostatism), diuresis (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226532\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to theophylline or any component of the formulation; allergy to corn-related products (injection only).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindications (not in US labeling): Hypersensitivity to xanthine derivatives; coronary artery disease (where cardiac stimulation might prove harmful); peptic ulcers; coadministration with ephedrine in children.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226515\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Theophylline toxicity: Severe and potentially fatal theophylline toxicity may occur if reduced theophylline clearance occurs. Theophylline clearance may be decreased in patients with acute pulmonary edema, heart failure, cor pulmonale, fever (&ge;102&deg;F for &ge;24 hours or lesser temperature elevations for longer periods), hepatic disease, acute hepatitis, cirrhosis, hypothyroidism, sepsis with multiorgan failure, shock, neonates (term and premature), infants &lt;3 months of age with decreased renal function, infants &lt;1 year of age, elderly &gt;60 years of age, and patients following cessation of smoking. Consider benefits versus risks and the need for more intensive monitoring in these patients; reduced infusion rate required. If a patient develops signs and symptoms of theophylline toxicity (eg, nausea or persistent, repetitive vomiting), a serum theophylline level should be measured immediately and subsequent doses withheld.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiac arrhythmias (excluding bradyarrhythmias); use may exacerbate arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cystic fibrosis: Use with caution in patients with cystic fibrosis; increased theophylline clearance may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment (eg, cirrhosis, acute hepatitis, cholestasis); risk of severe and potentially fatal theophylline toxicity is increased; theophylline clearance is decreased &ge;50% in these patients. Dose reduction and frequent monitoring of serum theophylline concentration are required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism; increased theophylline clearance may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; use may exacerbate peptic ulcer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with seizure disorders; use may exacerbate seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use extreme caution in the elderly; these patients are at greater risk of serious theophylline toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Select dose with caution and with frequent monitoring of concentrations (especially &lt;1 year); rate of clearance is highly variable in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Do not increase dose in response to acute exacerbation of symptoms unless steady state serum theophylline concentration is &lt;10 mcg/mL. As the rate of theophylline clearance may be dose-dependent, an increase in dose based upon a subtherapeutic serum concentration measurement should be limited to ~25% increase of the previous infusion rate or daily dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226596\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (major), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226520\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12831&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of Theophylline Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adalimumab: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adenosine: Theophylline Derivatives may diminish the therapeutic effect of Adenosine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May increase the serum concentration of Theophylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithyroid Agents: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzodiazepines: Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Theophylline Derivatives. Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. Management: Seek alternatives to this combination when possible.  If these agents are used together, monitor closely for decreased serum concentrations/therapeutic effects of both medications.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inducers (Moderate): May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May increase the serum concentration of Theophylline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Theophylline Derivatives may enhance the adverse/toxic effect of Doxofylline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Febuxostat: May increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Formoterol: Theophylline Derivatives may enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Fosphenytoin. Management: Seek alternatives when possible. If used together, monitor for decreased concentrations/effects of phenytoin or theophylline if the other agent is initiated/dose increased, or increased concentrations/effects if the other is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indacaterol: Theophylline Derivatives may enhance the adverse/toxic effect of Indacaterol. Theophylline Derivatives may enhance the hypokalemic effect of Indacaterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interferons: May decrease the metabolism of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoproterenol: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Theophylline Derivatives may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May decrease the metabolism of Theophylline Derivatives.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin; Telithromycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May decrease the serum concentration of Theophylline. Metreleptin may increase the serum concentration of Theophylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mexiletine: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olodaterol: Theophylline Derivatives may enhance the adverse/toxic effect of Olodaterol. Theophylline Derivatives may enhance the hypokalemic effect of Olodaterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pancuronium: Theophylline Derivatives may enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium.  Management: Pancuronium dosage adjustment may be necessary to induce paralysis  in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pefloxacin: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Theophylline Derivatives. Theophylline Derivatives may decrease the serum concentration of Phenytoin. Management: Seek alternatives when possible. If used together, monitor for decreased concentrations/effects of phenytoin or theophylline if the other agent is initiated/dose increased, or increased concentrations/effects if the other is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May decrease the serum concentration of Theophylline Derivatives.<b> Exceptions: </b>Fosamprenavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.<b> Exceptions: </b>Delafloxacin; Gemifloxacin; LevoFLOXacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Pefloxacin; Sparfloxacin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regadenoson: Theophylline may diminish the vasodilatory effect of Regadenoson. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Theophylline Derivatives may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of Theophylline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: May decrease the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiabendazole: May decrease the metabolism of Theophylline Derivatives.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: May increase the metabolism of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticlopidine: May increase the serum concentration of Theophylline Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). Management: Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zafirlukast: Theophylline Derivatives may decrease the serum concentration of Zafirlukast. Zafirlukast may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zileuton: May increase the serum concentration of Theophylline. Management: Reduce theophylline dose by 50% upon initiation of zileuton therapy. If theophylline is added to existing zileuton therapy, use a lower starting dose. Monitor for increased serum concentrations and effects of theophylline.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226548\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethanol: Ethanol may decrease theophylline clearance. Management: Avoid or limit ethanol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: Theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef; a high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline. Management: Avoid extremes of dietary protein and carbohydrate intake.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226521\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226536\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects have been observed in animal reproduction studies. Theophylline crosses the placenta; adverse effects may be seen in the newborn. Use is generally safe when used at the recommended doses (serum concentrations 5 to 12 mcg/mL) however maternal adverse events may be increased and efficacy may be decreased in pregnant women. Theophylline metabolism may change during pregnancy; the half-life is similar to that observed in otherwise healthy, nonsmoking adults with asthma during the first and second trimesters (~8.7 hours), but may increase to 13 hours (range: 8 to 18 hours) during the third trimester. The volume of distribution is also increased during the third trimester. Monitor serum levels. The recommendations for the use of theophylline in pregnant women with asthma are similar to those used in nonpregnant adults (National Heart, Lung, and Blood Institute Guidelines 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062537\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory rate, heart rate, serum theophylline concentration, pulmonary function tests, arterial or capillary blood gases (if applicable); number and severity of apnea spells (apnea of prematurity)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062541\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic concentrations:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asthma: 5-15 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Apnea of prematurity: 6-12 mcg/mL; goal concentration is reduced due to decreased protein binding and higher free fraction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toxic concentration: &gt;20 mcg/mL</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Guidelines for Drawing Theophylline Serum Samples</caption>\n      <col></col>\n      <col></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dosage Form</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">When to Obtain Sample<sup>A</sup></p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"2\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>A</sup>The time to achieve steady-state serum concentrations is prolonged in patients with longer half-lives (eg, infants and adults with cardiac or liver failure (see theophylline half-life). In these patients, serum theophylline concentrations should be drawn after 48-72 hours of therapy; serum concentrations may need to be done prior to steady-state to assess the patient's current progress or evaluate potential toxicity.</p></td></tr></tfoot>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">IV bolus</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">30 minutes after end of 30-minute infusion</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">IV continuous infusion</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">12-24 hours after initiation of infusion</p></td></tr>\n        <tr>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Oral immediate release formulations</p></td>\n          <td align=\"left\">\n            <p style=\"text-indent:0em;\">Peak: 1 hour postdose after at least 1 day of therapy</p>\n            <p style=\"text-indent:0em;\">Trough: Just before a dose after at least 1 day of therapy</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226514\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Theophylline has two distinct actions; smooth muscle relaxation (ie, bronchodilation) and suppression of the response of the airways to stimuli (ie, non-bronchodilator prophylactic effects). Bronchodilation is mediated by inhibition of two isoenzymes, phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilation effects are mediated through other molecular mechanisms. Theophylline increases the force of contraction of diaphragmatic muscles through enhancement of calcium uptake through adenosine-mediated channels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226531\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral (solution and immediate release): Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: ~0.45 L/kg based on ideal body weight; distributes poorly into body fat; V<sub>d</sub> may increase in premature neonates, hepatic cirrhosis, acidemia (uncorrected), elderly, and third trimester of pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via demethylation (CYP 1A2) and hydroxylation (CYP 2E1 and 3A4); forms active metabolites (caffeine and 3-methylxanthine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~40%, primarily to albumin; decreased in neonates (due to a greater percentage of fetal albumin), hepatic cirrhosis, acidemia (uncorrected), third trimester of pregnancy, and elderly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination (Hendeles 1995): Highly variable and dependent upon age, hepatic function, cardiac function, lung disease, and smoking history</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature infants, postnatal age 3 to 15 days: 30 hours (range: 17 to 43 hours); Premature infants, postnatal age 25 to 57 days: 20 hours (range: 9.4 to 30.6 hours); Term infants, postnatal age 1 to 2 days: 25.7 hours (range: 25 to 26.5 hours); Term infants, postnatal age 3 to 30 weeks: 11 hours (range: 6 to 29 hours); Children 1 to 4 years: 3.4 hours (range: 1.2 to 5.6 hours); Children and Adolescents 6 to 17 years: 3.7 hours (range: 1.5 to 5.9 hours); Adults &ge;18 years to &le;60 years (nonsmoking, asthmatic, otherwise healthy): 8.7 hours (range: 6.1 to 12.8 hours); Elderly &gt;60 years (nonsmoking, healthy): 9.8 hours (range: 1.6 to 18 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral (solution and immediate release): 1 to 2 hours; IV: Within 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~50% as unchanged drug [Neonates]; ~10% as unchanged drug [Infants &gt;3 months, Adolescents, and Adults])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Certain conditions may significantly alter theophylline clearance; severe and potentially fatal theophylline toxicity may occur if reduced theophylline clearance occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Decreased theophylline clearance: Neonates; infants &lt;3 months with decreased renal function; infants &lt;1 year; elderly &gt;60 years; acute pulmonary edema, cor pulmonale; fever (&ge; 102&deg;F for &ge;24 hours or lesser temperature elevations for longer periods); heart failure; hepatic impairment (eg, cirrhosis, acute hepatitis, cholestasis); hypothyroidism; patients following cessation of smoking; sepsis with multiple organ failure; shock; third trimester of pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Increased theophylline clearance: Hyperthyroidism; cystic fibrosis; smoking (ie, marijuana or tobacco).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10951004\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> An alcohol-containing commercial oral solution is available (80 mg/15 mL).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 5 mg/mL oral suspension may be made with tablets. Crush one 300 mg extended release tablet in a mortar and reduce to a fine powder. Add small portions of a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; and mix to a uniform paste; mix while adding the vehicle in equal proportions to <b>almost</b> 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add sufficient quantity of vehicle to make 60 mL. Label &quot;shake well&quot;. Stable for 90 days at room temperature.</p>\n    <div class=\"reference\">Johnson CE, VanDeKoppel S, and Myers E, &quot;Stability of Anhydrous Theophylline in Extemporaneously Prepared Alcohol-Free Oral Suspensions,&quot; <i>Am J Health-Syst Pharm</i>, 2005, 62(23):2518-20.<span class=\"pubmed-id\">16303910</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226535\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Theo-24 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $239.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $356.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $438.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $616.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Elixir</b> (Elixophyllin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/15 mL (473 mL): $394.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Theophylline in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 mg/mL 5% (500 mL): $4.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Theophylline Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg/15 mL (473 mL): $111.75</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Theochron Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $23.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $36.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $60.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Theophylline ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $44.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (500): $277.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $68.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 mg (100): $94.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Theophylline ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (100): $135.76</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (100): $196.17</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F226539\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aerobin (DE);</li>\n      <li>Austyn (KR);</li>\n      <li>Bronchoretard (DE);</li>\n      <li>Bronsolvan (ID);</li>\n      <li>Bufabron (ID);</li>\n      <li>Contine (BD);</li>\n      <li>Diaphyllin (VN);</li>\n      <li>Ditenaten (DE);</li>\n      <li>Duralyn-CR (TH);</li>\n      <li>Egifilin (HU);</li>\n      <li>Elixifilin (ES);</li>\n      <li>Elixine (CL);</li>\n      <li>Eteophyl (KR);</li>\n      <li>Etipramid (CN);</li>\n      <li>Euphyllin (PL);</li>\n      <li>Euphyllin Retard (ID);</li>\n      <li>Euphyllin Retard Mite (ID);</li>\n      <li>Euphylong (AE, BH, CY, EG, HU, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Euphylong Retardkaps (DE);</li>\n      <li>Franol (TH);</li>\n      <li>Frezma (BD);</li>\n      <li>Lasma (AE, BH, CY, EG, GB, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Meridian AP (UY);</li>\n      <li>Nefoben (AR);</li>\n      <li>Neoffilin (UA);</li>\n      <li>Neulin SA (MT);</li>\n      <li>Neulin-SR (NZ, TW);</li>\n      <li>Nosma (TW);</li>\n      <li>Nuelin (AU, BB, BM, BS, BZ, DK, FI, GY, JM, LK, NZ, PH, PR, SG, SR, TT, VE);</li>\n      <li>Nuelin SA (AE, BF, BH, BJ, CI, CR, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PA, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Nuelin SR (AE, AU, BH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SG, SY, TH, YE);</li>\n      <li>Pediaphyllin PL (LU);</li>\n      <li>Pellapenta (LK);</li>\n      <li>Pharmafil (MX);</li>\n      <li>Phylobid (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Quibron T SR (ID);</li>\n      <li>Quibron TSR (LK);</li>\n      <li>Respicur retard (AT);</li>\n      <li>Retafyllin (EE, HU);</li>\n      <li>Slo-Phyllin (AE, BH, CY, EG, GB, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Slo-Theo (HK);</li>\n      <li>Solosin (DE);</li>\n      <li>Somofillina (IT);</li>\n      <li>Teoclear (KR);</li>\n      <li>Teoclear LA (AR);</li>\n      <li>Teofilina Retard (CO, EC);</li>\n      <li>Teolex (BD);</li>\n      <li>Teolex CR (BD);</li>\n      <li>Teolex SR (BD);</li>\n      <li>Teolin (HR);</li>\n      <li>Teolong (BR, PY);</li>\n      <li>Teosona (AR);</li>\n      <li>Teotard (BG, EE, HR, LV, RO, RU, UA);</li>\n      <li>Teromol Retard (ES);</li>\n      <li>Theo PA (IN);</li>\n      <li>Theo-2 (BE, LU);</li>\n      <li>Theo-24 (IT);</li>\n      <li>Theo-Bros (GR);</li>\n      <li>Theo-Dur (AR, CZ, DK, ES, FI, GR, IT, JP, LU, MT, MY, NO, PK, QA, SA, SE, TR);</li>\n      <li>Theoclear (KR);</li>\n      <li>Theolair (CH, ES, IT, NL);</li>\n      <li>Theolair LA (LU);</li>\n      <li>Theolair S (PE);</li>\n      <li>Theolan (KR);</li>\n      <li>Theolin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Theolin SR (SG);</li>\n      <li>Theolong (JP);</li>\n      <li>Theonate (BD);</li>\n      <li>Theophar (AE, BH, KW, QA, SA);</li>\n      <li>Theophtard (HU);</li>\n      <li>Theophyllin-ratiopharm (LU);</li>\n      <li>Theophylline Bruneau (LU);</li>\n      <li>Theoplus Retard (AT, GR);</li>\n      <li>Theospirex (HU);</li>\n      <li>Theospirex Retard (AT);</li>\n      <li>Theostat (LU);</li>\n      <li>Theostat LP (FR);</li>\n      <li>Theotard (IL);</li>\n      <li>Uni-Dur (HR);</li>\n      <li>Unicontin (PT);</li>\n      <li>Unicontin-400 Continus (IN);</li>\n      <li>Unidur (AE);</li>\n      <li>Unifyl Retard (CH);</li>\n      <li>Uniphyllin (TW);</li>\n      <li>Uniphyllin Continus (AE, BF, BH, BJ, CI, CY, EG, ET, GB, GH, GM, GN, IE, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Uniphylline (JO);</li>\n      <li>Xanthium (LU);</li>\n      <li>Zepholin (IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt-Mehta V and Schumacher RE, &ldquo;Treatment of Apnea of Prematurity,&rdquo; <i>Paediatr Drugs</i>, 2003, 5(3):195-210. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/12608884 /pubmed\" target=\"_blank\" id=\"12608884 \">12608884 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hendeles L, Jenkins J, and Temple R, &ldquo;Revised FDA Labeling Guideline for Theophylline Oral Dosage Forms,&rdquo; <i>Pharmacotherapy</i>, 1995, 15(4):409-427. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/7479193 /pubmed\" target=\"_blank\" id=\"7479193 \">7479193 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henderson-Smart DJ and De Paoli AG, &quot;Methylxanthine Treatment for Apnoea in Preterm Infants,&quot; <i>Cochrane Database Syst Rev</i>, 2010, 12:CD000140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/21154343/pubmed\" target=\"_blank\" id=\"21154343\">21154343</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearney TE, Manoguerra AS, Curtis GP, et al, &ldquo;Theophylline Toxicity and the Beta-Adrenergic System,&rdquo; <i>Ann Intern Med</i>, 1985, 102(6):766-9. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/2986507/pubmed\" target=\"_blank\" id=\"2986507\">2986507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kraus DM, Fischer JH, Reitz SJ, et al, &ldquo;Alterations in Theophylline Metabolism During the First Year of Life,&rdquo; <i>Clin Pharmacol Ther</i>, 1993, 54(4):351-9. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/8222476 /pubmed\" target=\"_blank\" id=\"8222476 \">8222476 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo; <i>Clinical Practice Guidelines</i>, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program Asthma and Pregnancy Working Group, &ldquo;NAEPP Expert Panel Report. Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment - 2004 Update,&rdquo; <i>J Allergy Clin Immunol</i>,  2005, 115(1):34-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/15637545/pubmed\" target=\"_blank\" id=\"15637545\">15637545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skouroliakou M, Bacopoulou F, and Markantonis SL, &quot;Caffeine Versus Theophylline for Apnea of Prematurity: A Randomised Controlled Trial,&quot; <i>J Paediatr Child Health</i>, 2009, 45(10):587-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/19751376/pubmed\" target=\"_blank\" id=\"19751376\">19751376</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Upton RA, &ldquo;Pharmacokinetic Interactions Between Theophylline and Other Medication (Part I),&rdquo; <i>Clin Pharmacokinet</i>, 1991, 20(1):66-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/1674242/pubmed\" target=\"_blank\" id=\"1674242\">1674242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/theophylline-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12831 Version 203.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F226552\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F226553\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062538\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445184\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062531\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F226525\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F226511\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062543\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6871827\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062542\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F226604\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F226532\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F226515\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F226596\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F226520\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F226548\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F226521\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F226536\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062537\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1062541\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F226514\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F226531\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10951004\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F226535\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F226539\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12831|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=theophylline-drug-information\" class=\"drug drug_general\">Theophylline: Drug information</a></li><li><a href=\"topic.htm?path=theophylline-patient-drug-information\" class=\"drug drug_patient\">Theophylline: Patient drug information</a></li></ul></div></div>","javascript":null}